Objectives: High levels of HIV-1 viremia exist in peripheral blood during acute and early infection; however, data on HIV-1 viral loads in female genital secretions during this period are sparse.
Introduction
Early HIV infection represents a dynamic period during which infection disseminates from local lymph nodes and HIV viremia initially climbs to very high levels followed by a decline to an equilibrium (viral setpoint). The high viremia levels in peripheral blood during early infection appear to be associated with high levels of HIV transmission [1] . In addition, the level of viral setpoint is an important predictor of subsequent HIV disease progression [2] [3] [4] .
Although this dynamic period has been well documented in the peripheral blood, little is known about the dynamic of genital viral loads during early infection (the first 6 months). Genital viral loads, the biologic mediator between plasma viral loads and HIV transmission, are important to understand, particularly during the early infection period. Two recent studies conducted in men [5] and women [6] have documented high genital viral loads during this period. However, it is unclear whether and when a setpoint is attained in the genital compartment. It is also unclear whether there are modifiable risk factors that influence genital viral loads during the early infection period.
Few studies have examined factors associated with plasma viral setpoint. A study conducted among Kenyan sex workers [7] found that use of the injectable progestin contraceptive depot medroxyprogesterone acetate (DMPA) at the time of HIV infection was associated with a higher plasma viral load setpoint, whereas the presence of genital ulcer disease (GUD) during early HIV infection was associated with higher subsequent plasma viral loads. However, these findings have not been corroborated.
HIV-1 genital shedding among women can be affected by both systemic (pregnancy, hormonal contraceptive use, CD4 lymphocyte levels, plasma viral loads, HAART, HIV-1 subtype) [8] [9] [10] [11] [12] [13] [14] [15] and local factors (menstruation, genital inflammation, cervical and vaginal infections, abnormal vaginal flora) [6, 8, 9, 13, [16] [17] [18] [19] [20] . However, factors associated with HIV-1 genital shedding during early HIV-1 infection have not been reported.
We studied the relationship between plasma and genital HIV viral loads among Ugandan and Zimbabwean women during acute and early (first 6 months) HIV infection and examined factors, including hormonal contraceptive use, that may be associated with plasma and genital viral loads during this period and could impact subsequent HIV-1 disease progression or transmission. Data were drawn from a prospective cohort study of contraception and HIV acquisition -the Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study [21] -and a subsequent study conducted among the women who became HIV-infected -the Hormonal Contraception and HIV-1 Genital Shedding and Disease Progression among Women with Primary HIV Infection (GS) Study.
Methods
The research was approved by the institutional review boards of the collaborating institutions. All participants provided written informed consent prior to study participation.
Study population and procedures
The study population was drawn from women who enrolled in the GS Study during the period from 2001 to 2007. The 188 GS Study participants were HIV-infected (with known infection dates), ages 18-45 years, were using either no hormonal method, combined oral contraceptives (COCs) (low-dose pills containing 30 mg ethinylestradiol and 150 mg of levonorgestrel) or DMPA (150 mg administered quarterly). Women were ineligible for enrollment if they had a hysterectomy, a spontaneous or induced abortion within 10 days of enrollment, or were using hormonal contraception besides COCs or DMPA.
GS Study procedures were similar to those previously described for the HC-HIV Study [21] . Briefly, when HC-HIV study participants were notified of their HIVinfection, they were informed about the GS Study. Interested women were scheduled as soon as possible for a GS enrollment visit, where informed consent procedures were conducted. At enrollment, participants were interviewed in the local language to collect sexual behavior, reproductive health, and contraceptive history data. We provided contraceptive, HIV-risk reduction and condom use counseling, and free contraceptives and condoms. Study clinicians conducted a standardized physical (including pelvic) examination and collected specimens for reproductive tract infections, pregnancy testing, Pap smears, lymphocyte phenotyping, and plasma and cervical viral loads. Testing for reproductive tract infection and pregnancy was done as previously described [21] . Participants were treated onsite for vaginal infections; women diagnosed with asymptomatic chlamydia, gonorrhea or syphilis were recalled for treatment.
Follow-up visits were conducted at 4, 8, and 12 weeks following enrollment and at 12-week intervals thereafter. Follow-up procedures were similar to those at enrollment and included testing for all sexually transmitted infections (STIs; syphilis testing and Pap smears were conducted every 6 months).
Beginning in 2003, women who developed severe symptoms of HIV infection (WHO clinical stage IV or advanced stage III disease) or who had successive CD4 lymphocyte counts of 200 cells/ml or below were offered HAART and trimethoprimsulfamethoxazole (for prophylaxis against bacterial infections). At each study visit, participants were provided with daily multivitamins and iron.
Analysis population and variable definition
The analysis population for the calculation of plasma and cervical viral setpoints included 188 Ugandan and Zimbabwean women contributing 1042 plasma and 813 cervical specimens within 24 months of HIV-1 infection. The analysis population for comparison of plasma and genital viral loads during early infection included 173 women providing 528 plasma specimens and 159 women providing 471 cervical specimens evaluated within 6 months of HIV-1 infection.
HIV PCR was performed on samples from visits prior to HIV seroconversion to establish infection timing [21] . For women whose seroconversion visit was also their first PCR-positive visit, HIV-1 infection dates were estimated as the midpoint between this and the previous visit. Because HIV testing was conducted every 12 weeks in the HC-HIV Study, estimated infection date was usually within a 6-week window of the actual infection date. We defined acute infections as those that were serologically negative but HIV PCR-positive. We estimated acute infections to occur 15 days prior to the first PCRpositive visit.
Contraceptive exposure definition varied by analysis. For analyses associated with viral setpoint, exposed women were those using COCs or DMPA between the two study visits when the HIV infection occurred. For the comparison of plasma and genital viral loads, exposed women were those using COCs or DMPA during the 12-week period prior to the visit when the specimen was collected. When women switched from DMPA to the nonhormonal group, we calculated the DMPA exposure as 120 days from the last injection.
Viral RNA load determination
We obtained samples for cervical viral loads by inserting a dacron swab into the endocervix and rotating the swab for 3-5 s [22] . The swabs were then stored in 1 ml of RNAlater (Applied Biosystems Inc., Foster City, California, USA) at À708C. Due to the viscosity of RNAlater, virus was pelleted by diluting the 500 ml of RNAlater to a final volume of 8 ml with RPMI. After centrifugation at 23 600 g for 3 h at 48C, the entire viral pellet was resuspended and viral loads estimated according to the ultrasensitive (lower limit of detection ¼ 50 copies/ ml) procedure of the Roche Amplicor HIV-1 Monitor Test, version 1.5. Details of this methodology are provided in the Supplementary methods. Plasma viral loads were also performed using the same Roche Amplicor version 1.5 assay as per the manufacturers' protocol. If plasma viral loads were below 400 copies/ml, repeat analyses were performed using the ultrasensitive procedure to obtain a sensitivity of 50 copies/ml. Likewise, plasma was diluted 100-fold and the standard Roche Amplicor 1.5 assay was repeated if the initial viral load was more than 750 000 copies/ml.
HIV-1 DNA sequencing, subtype determination, and prediction of co-receptor usage
To determine HIV-1 subtypes, DNA was extracted from whole blood using the Qiagen DNA extraction kit (Qiagen Inc., Gaithersberg, Maryland, USA). The env gene was PCR amplified in the C2-V3 region using an external-nested PCR amplification with primer pairs ENV B-ED14 (external) and ENV1-ENV2 (nested) [23] . The primer sequences are provided in Supplementary  Table 1 . PCR products were purified using the Qiagen PCR purification kit then sequenced using the Beckman Coulter CEQ 8000 sequencer using the ENV1 forward primer. Sequences were analyzed and edited as described in the Supplementary methods. These HIV-1 sequences are available in GenBank (numbers are currently being obtained).
Statistical methods
We used the Loess procedure to estimate the mean level and timing of plasma and cervical viral setpoints [24] . A marginal model with the generalized estimating equation (GEE) approach (to account for repeated measurements on the same individual) was used to determine the plasma viral setpoint among various exposure groups and to model the association between predictors (the difference in viral setpoint between those with and without a specified characteristic) and plasma HIV-1 viral load within the defined period.
We used Spearman's correlation coefficient to measure correlation between plasma and genital viral loads. We used marginal models using the GEE approach for hypothesis testing of the comparison of genital viral loads levels over time and to evaluate the impact of covariates on cervical HIV-1 RNA levels during early ( 6 months) HIV infection.
Because all Zimbabwean participants with completed subtyping (n ¼ 72) are subtype C, we imputed subtypes for the remaining 57 Zimbabwean participants. Additionally, two Ugandan participants with subtype C infections were dropped from multivariate modeling due to small group size.
Results
Of the 188 women contributing data to these analyses, 129 (69%) were Zimbabwean and 59 (31%) were Ugandan.
Participant characteristics at HIV seroconversion visit
At HIV seroconversion, the median age was 25 years and median education was 10 years (Table 1) . About two-thirds of the women used hormonal contraception including DMPA (40%) and COCs (30%). Only 4% were currently pregnant, whereas 13% currently breastfed. Few participants reported multiple sex partners (3%), commercial sex (2%), or having a new sex partner (4%). One quarter reported consistent condom use during the previous 3 months. The prevalence of STIs was high: 13 women (7%) had a chlamydial infection, 24 (14%) had gonorrhea, 55 (31%) had bacterial vaginosis, and most (85%) were herpes simplex virus type 2 (HSV-2)-positive.
At the HIV infection visit, nonhormonal participants were slightly older and more likely to be pregnant than COC or DMPA users (Table 1) . Participants using nonhormonal contraception also had higher levels of sexual risk including more commercial sex and a higher number of partners spending nights away from home but also reported more consistent condom use (49%) than hormonal contraceptive users (13%). No important differences were found in STI prevalence between contraceptive groups (Table 1) .
All Zimbabwean participants had subtype C HIV infections, whereas 34 Ugandan participants (63%) had subtype A, 18 (33%) had subtype D, and 2 (4%) had subtype C infections. A subset of these sequences is presented in a phylogenetic neighbor-joining tree (see Supplementary methods).
CXCR4 usage or dual tropism was predicted in only four participants at the time of early infection in this cohort [25, 26] . Of these four participants, one was subtype A, one subtype D, and two subtype C (both from Zimbabwe).
Analysis of HIV viral setpoint
We estimated the population mean HIV-1 plasma viral setpoint to be 4.20 log 10 HIV-1 copies/ml (95% CI 4.04-4.35) at 121 days (95% CI 91-137) from the HIV infection date ( Fig. 1 ). Mean viral load at setpoint for participants with dual tropic virus (4.34 copies/ml) was similar to that for the entire analysis population. The crude mean and standard error for HIV plasma viral load (from 121 days to 24 months) was 4.17 log 10 HIV-1 copies/ml (SE ¼ 0.04). Multivariable analysis was used to assess the effect of a variety of factors on the estimated mean setpoint. In multivariable analysis, contraceptive (including COC and DMPA) use, STI (chlamydia and gonorrhea), and sexual risk behaviors at the time of HIV infection were not significantly associated with the plasma viral setpoint ( Table 2 ). Younger age (18-24 years) was associated with a decrease in the mean viral setpoint of À0.30 log 10 HIV-1 copies/ml (95% CI À0.58 to À0.02) compared with older age and subtype D (compared to subtype A) infection was associated with an increase in the mean viral setpoint of þ0.48 log 10 HIV-1 copies/ml (95% CI 0.01-0.94). Both pregnancy (þ0.48 copies/ml) and breastfeeding at the time of infection (þ0.54 copies/ml) were also significantly associated with an increase in mean viral setpoint.
Following the establishment of the mean plasma viral setpoint, subsequent plasma viral loads increased only slightly (þ0.005 log 10 HIV-1 copies/ml per month; P ¼ 0.24) through 24 months.
We also found a significant difference in the time to mean plasma viral setpoint by HIV-1 subtype. Time to setpoint was fastest for subtype D (100 days; 95% CI 67-109 days), followed by subtype A (139 days; 95% CI 109-157 days), and was slowest for subtype C infections (183 days; 95% CI 152-200 days).
Genital viral loads during early infection
We observed a direct correlation between HIV-1 cervical and plasma viral RNA levels during early infection (Spearman's r ¼ 0.47; P < 0.0001) ( Fig. 1 ). We found an equilibrium level or 'setpoint' among genital secretions similar to that in the peripheral blood. The mean cervical setpoint was 1.64 log 10 HIV-1 copies/swab (95% CI 1.46-1.82) and occurred at 174 days (95% CI 145-194) from the estimated infection date. Similar to plasma viral loads, cervical viral loads were higher during acute infection (mean of 3.01 log 10 copies/swab) than during periods 1-2, 2-4, and 4-6 months after infection (means of 2.30, 2.00, and 1.92 log 10 HIV-1 copies/swab; P ¼ 0.03, P < 0.01, and P < 0.01, respectively) ( Table 3 ). Cervical specimens taken 1-2 months after HIV-1 infection had higher mean viral loads than specimens taken 2-4 and 4-6 months from time of infection (P < 0.01). The comparisons were similar when each country was considered individually. Following the establishment of a setpoint at 174 days after infection, cervical viral loads did not change significantly (þ0.001 log 10 HIV-1 copies/swab per month; P ¼ 0.85) through 24 months.
In multivariable analysis, having a nonviral STI (chlamydia, gonorrhea, or trichomoniasis) (þ0.29 log 10 copies/swab; P ¼ 0.03), a partner spending nights away from home (þ 0.22 log 10 copies/swab; P < 0.01), unprotected sex within 3 days (þ0.21 log 10 copies/swab; P ¼ 0.06), and Zimbabwe-subtype C infection (þ0.26 log 10 copies/swab; P ¼ 0.05) were associated with increased cervical viral loads ( Table 4 ). The effect of subtype D infection on mean cervical viral load (þ0.30 log 10 copies/swab) was of similar magnitude as subtype C infection but was not statistically significant (P ¼ 0.09). Greater duration since HIV infection (À0.11 log 10 copies/swab per month; P < 0.01) was associated with decreased cervical viral loads. There was no association between DMPA (þ0.12 log 10 copies/ swab; P ¼ 0.35) or COC use (þ0.08 log 10 copies/swab; P ¼ 0.50) and cervical HIV-1 viral loads. Age, pregnancy, breastfeeding, and genital ulcer disease were also not significantly associated with cervical HIV-1 levels.
We also considered our final multivariate model predicting cervical viral loads adjusted for plasma viral load. Higher plasma viral loads were strongly associated with higher mean cervical loads (þ0.30 log 10 copies/ swab; P ¼ <0.001) and time since HIV infection remained strongly associated with decreased mean cervical loads (À0.09 log 10 copies/swab per month; P < 0.001). Having a partner who spent nights away from home also remained associated with higher cervical loads (þ0.20 log 10 copies/swab; P < 0.01). However, HIV-1 subtype, nonviral STIs, and having unprotected sex within the last 3 days were no longer significantly associated with mean cervical loads. Instead, breastfeeding (þ0.25 log 10 copies/swab; P ¼ 0.04) and the number of coital acts per month (15-29 acts: þ0.17 log 10 copies/ swab; P ¼ 0.04; >30 acts: þ0.35 log 10 copies/swab; P ¼ 0.18) were associated with higher cervical viral loads.
Discussion
We found that women in Uganda and Zimbabwe established a plasma viral setpoint of 4.20 log 10 HIV-1 copies/ml at 121 days and an analogous cervical viral 'setpoint' of 1.64 log 10 HIV-1 copies/swab at 174 days from estimated date of HIV-1 infection suggesting that setpoint is achieved later in the genital compartment than in the plasma. Cervical viral loads were strongly correlated with plasma viral loads during the first 6 months of HIV-1 infection (P < 0.0001) and were significantly higher (0.7-1.1 log 10 copies/ml higher) during acute infection than subsequently during the early infection period.
Our findings concerning the level and timing of the plasma viral setpoint are similar to those reported by other studies. For example, a study of 161 sex workers in Mombassa, Kenya, reported a median viral setpoint of 4.46 log 10 copies/ml attained at 4 months after infection 578 AIDS 2010, Vol 24 No 4 h Two Ugandan women with subtype C were excluded from multivariable model. [7] . A study of high-risk Kenyan men and women found a virus setpoint of 4.60 log 10 copies/ml at 209 days after infection [27] . Similarly, a study among newly HIVinfected adults in the United States estimated the viral setpoint at 4.56 log 10 copies/ml at 117 day after infection [24] .
We found that subtype D infection, pregnancy, and breastfeeding at the time of HIV infection were associated with a higher plasma viral setpoint, whereas young age was associated with a decreased plasma setpoint. These findings concerning predictors of plasma viral setpoint contrast with a previous study conducted among Kenyan sex workers. In that study, DMPA use was associated with a higher viral setpoint (compared with no use of hormonal contraception) but no association was reported between older age, pregnancy, breastfeeding, or subtype D infection and plasma viral setpoint [7] . Although no other analyses of predictors of viral setpoint exist, several studies have reported on predictors of HIV-1 disease progression. A Zambian study found an increased risk of disease progression (CD4 cell count <200 cells/ml or death) among women using hormonal contraception compared with women randomized to copper intrauterine devices [28] . Conversely, a study of postpartum Kenyan women found no differences in change in plasma viral load or CD4 cell counts among women initiating COCs or DMPA [29] . Additionally, several studies suggest that older age [30] and subtype D HIV-1 infection [31] [32] [33] [34] are associated with more rapid HIV-1 disease progression. On the contrary, most studies conclude that pregnancy, although causing transient CD4 cell count decline, is not associated with more rapid disease progression [35] [36] [37] [38] .
We found a dynamic in the female genital compartment similar to the plasma viral setpoint -high levels of HIV-1 genital viremia during acute infection falling to a steadystate level at about 6 months. Following the establishment of this 'setpoint', genital viral loads remained constant up to 2 years after infection. We are not aware of previous reports of a 'setpoint' in the genital compartment. Most previous studies have not had substantial genital viral load data from the acute and early infection periods. However, although it is well documented that the plasma viral setpoint is predictive of subsequent disease progression [2] [3] [4] , the utility of a genital 'setpoint' as a predictor of potential infectivity to a sex partner remains to be established.
Our findings corroborate recent reports of high levels of HIV-1 genital shedding early in infection in both women and men with declining levels thereafter [5, 6] . Genital and plasma viral loads have also been strongly correlated in other studies (r ¼ 0.4-0.7) [20, [39] [40] [41] ; plasma RNA load is often the factor most strongly associated with genital RNA load in multivariable models [40, 42] . However, the strong correlation between genital and plasma viral loads has not previously been clearly documented during early infection. Subtype C infection, nonviral STIs, having a partner who spends nights away from home, and recent unprotected sex were associated with higher cervical HIV-1 loads, whereas time since infection was associated with decreased cervical loads. Hormonal contraceptive (COC and DMPA) use was not associated with cervical viral loads during early HIV-1 infection. Our results corroborate the findings of much previous research. For example, previous studies have identified nonviral STIs [6, 9, 40, 43] , recent unprotected sex, and subtype C HIV-1 infection [16] as associated with higher genital viral loads. Our finding that hormonal contraception is not associated with HIV RNA genital shedding also agrees with those of most (but not all) previous studies suggesting that hormonal contraception appears to be associated with shedding of HIV-infected cells (measured by HIV-1 DNA) but not cell-free virus (measured by HIV-1 RNA) in the female genital tract [8] [9] [10] 12, 15, 20] . However, we are unaware of previous research assessing correlates of HIV-1 genital shedding among women during early infection.
Our study has a number of important strengths. The study was prospective with samples for both plasma and cervical viral loads being collected every 12 weeks beginning before HIV infection. We measured HIV infection timing with precision by conducting HIV PCR testing on serial samples that were serologically negative. We accurately measured many variables that were potentially associated with both HIV viral setpoint and genital shedding, including hormonal contraceptive use and reproductive tract infections. We also measured viral subtype from 580 AIDS 2010, Vol 24 No 4 Table 4 . Analyses of the predictor effects of HIV-1 endocervical viral load during early HIV-1 infection (data up to 6 months).
Unadjusted analysis a Adjusted analysis b
Variable log 10 RNA copies/ml (95% CI) (n ¼ 442) c P log 10 RNA copies/ml (95% CI) (n ¼ 420) c P women with a variety of non-B HIV-1 clades. Finally, we enrolled women seeking family planning services in two sub-Saharan countries. This allows for greater generalizability of study results than a study population drawn from a selected high-risk group (e.g., sex workers).
Our study also had limitations. We used RNAlater as storage media for cervical specimens. This resulted in lower cervical viral load levels compared with specimens collected in dimethylsulfoxide (compared at later study visits). We only sequenced the C2-V3 region of env and thus cannot fully explore the issue of recombinant viruses. Also, some women had unprotected sex during the 3 days prior to their study visit and thus measured genital viral loads at these visits could have been a combination of a participant's and her partner's viral load. However, we measured unprotected sex acts in the last 3 days and adjusted for this in our model of cervical viral loads and believe that this improves the accuracy of our estimates of predictors of cervical viral loads (Table 4 ). Finally, we are unable to address whether a genital viral 'setpoint' is meaningful in terms of long-term transmission risk.
In summary, we found that cervical HIV-1 viral loads were highest during acute infection and then declined up to 6 months after infection when they appeared to reach a setpoint. 
Supplementary Methods:

Viral RNA load determination
We obtained samples for cervical viral loads by inserting a dacron swab into the endocervix and rotating the swab for 3-5 seconds [1] . The swabs were then stored in 1 ml of RNALater at -708C. Due to the viscosity of RNALater, virus was pelleted by diluting the 500ml of RNAlater to a final volume of 8 ml with RPMI. After centrifugation at 23,600 x G for 3 hours at 48C, the entire viral pellet was resuspended and viral loads estimated according to the ultrasensitive procedure of the Roche Amplicor HIV-1 Monitor Test, version 1.5. This protocol was devised after testing for the optimal dilution of RNA later (undiluted, 1:1 with PRMI, 1:4, and 1:10), optimal centrifugation Supplementary Table 1 . Sequence   ENV B  AGAAAGAGCAGAAGACAGTGGCAATGA  ED14  TCTTGCCTGGAGCTGTTTGATGCCCCAGAC  ENV1  GGTATCCTTTGAGCCAATTCC  ENV2 AGAAAAATTCCCCTCCACAAT Supplementary Figure 1 . Phylogenetic tree on a subset of HIV-1 C2-V3 sequences derived from newly infected Ugandan and Zimbabwean women. The env gene was PCR amplified in the C2-V3 region and then sequenced using oligonucleotide primers described in supplementary table 1. Neighbor joining phylogenetic trees were constructed from sequence alignments using ClustalX and Treeview. Sequences have been deposited in Genbank (see Materials and Methods). HIV-1 sequences and subtypes of C2-V3 sequences derived from Ugandan (A) and Zimbabwean cohorts (B). Branch points on the tree lacking labels indicate an individual patient sequence from the cohort. Labels indicate the reference strains in the phylogenetic trees. Bootstrapping (1000 trees) were performed but not presented. time (1, 2, 3 and 4h) and g force (17000, 23600, and 33600). For these experiments, RNA later was ''spiked'' with swabs soaked in plasma with known viral RNA load or ''spiked'' directly with the same plasma sample. Viral RNA load was highest and recovery was nearly 100% when the spiked swab was placed in RNA later, diluted 1:10, and centrifuged at 23,600 x G for 3 h. Increases in g force to 33,600 and spin times greater than 4 h reduced detection of viral RNA levels by half. A manuscript is currently in preparation describing this revised methodology. The advantage to RNA later relates to stability of virus and ability to accurately quantify viral RNA levels even when the sample is stored at room temperature for 30 days prior to analysis (Bulime, Nankya, and Arts, personal communication). In contrast, recovery and detection of viral RNA levels drop by at least 10-fold in plasma stored at room temperature or even 48C for 30 days. Plasma viral loads were performed using the same Roche Amplicor version 1.5 assay as per the manufacturer's protocol. If plasma viral loads were < 400 copies/ml, repeat analyses were performed using the ultrasensitive procedure to obtain a sensitivity of 50 copies/ml. Likewise, plasma was diluted 100-fold and the standard Roche Amplicor 1.5 assay was repeated if the initial viral load was >750,000 copies/ml.
Oligonucleotide primer
HIV-1 DNA sequencing, subtype determination, and prediction of co-receptor usage
To determine HIV-1 subtypes, DNA was extracted from whole blood using the Qiagen DNA extraction kit (Qiagen Inc, Maryland) according to manufacturer's instructions. The env gene was PCR amplified in the C2-V3 region using an external-nested PCR amplification with primer pairs ENV B-ED14 (external) and ENV1-ENV2 (nested) [2] . The primer sequences are provided in the Supplementary Table 1 . PCR products were purified using the Qiagen PCR purification kit according to manufacturer's instructions and sequenced using the Beckman Coulter CEQ 8000 sequencer using the ENV1 forward primer. Sequences were analyzed and edited using Bioedit sequence editor version 7.0.5. These annotated sequences were then aligned with reference strains from the Los Alamos HIV sequence database using ClustalX and BioEdit. Neighbor-joining trees were constructed using TreeView ( Supplementary Figure 1) . Sequences were too short to detect any intersubtype recombination sites by RIP or SIMPLOT. The C2 -V3 nucleotide sequences alignments were then stripped of gaps and translated in all three frames to identify the open reading frame. The C2-V3 sequences were then scanned for any positive charged amino acids at positions 11 and 25 in the V3 loop (or 306 and 322 by HXB2 numbering in Env). A positive charged amino acid at either or both positions is >95% predictive of CXCR4-using or dual tropic HIV-1 isolate. The PSSM [3] and geno-2-pheno [4] tools were not used due to the poor testing of these algorithms on the co-receptor usage predictions for nonsubtype B isolates.
Previous studies involving full genome sequencing suggest approximately a 20% frequency of intersubtype recombination in the HIV-infected Ugandan population [5] [6] . However, HIV-1 sequences in the HIV-1 env gene, and in particular, the V3 loop may still be the determining factor for virulence [7] , tropism [8] , as well as the primary target for neutralizing antibodies [9] .
